HOWL Stock Analysis
HO
Uncovered
Werewolf Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is headquartered in Watertown, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2021-04-30. The firm is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. The Company’s product candidates include WTX-124, WTX-330 and WTX-613. The Company’s advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12). Its INDUKINE molecules for the treatment of solid tumors. The firm initiating a Phase I/Ib clinical trial for each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. WTX-613 is designed to have minimal activity in the periphery and is activated preferentially in the tumor microenvironment (TME) to release wild-type IFNα in the tumor and potentially stimulate an anti-tumor immune response.